HDAC9 and thyroid gland carcinoma: In this context, the MEK inhibitor AZD, BRAF V600E inhibitor PLX (vemurafenib), and HDAC inhibitor SAHA (vorinostat), which have been approved for the treatment of other human cancers, could reasonably be used as a combination therapy to restore radioiodine avidity for radioiodine treatment of radioiodine-refractory thyroid cancer.